These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35228870)

  • 21. Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5
    Majowicz A; Salas D; Zabaleta N; Rodríguez-Garcia E; González-Aseguinolaza G; Petry H; Ferreira V
    Mol Ther; 2017 Aug; 25(8):1831-1842. PubMed ID: 28596114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.
    Kruzik A; Fetahagic D; Hartlieb B; Dorn S; Koppensteiner H; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Mol Ther Methods Clin Dev; 2019 Sep; 14():126-133. PubMed ID: 31338384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral immune responses to AAV gene therapy in the ocular compartment.
    Whitehead M; Osborne A; Yu-Wai-Man P; Martin K
    Biol Rev Camb Philos Soc; 2021 Aug; 96(4):1616-1644. PubMed ID: 33837614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.
    Mimuro J; Mizukami H; Hishikawa S; Ikemoto T; Ishiwata A; Sakata A; Ohmori T; Madoiwa S; Ono F; Ozawa K; Sakata Y
    Mol Ther; 2013 Feb; 21(2):318-23. PubMed ID: 23247100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies in Patients With Heart Failure in the Cardiovascular Foundation of Colombia (ANVIAS): Study Protocol.
    Rincon MY; Prada CE; Lopez M; Castillo V; Echeverria LE; Serrano N
    JMIR Res Protoc; 2016 Jun; 5(2):e102. PubMed ID: 27282359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralisation of adeno-associated virus transduction by human vitreous humour.
    Andrzejewski S; Moyle PM; Stringer BW; Steel JC; Layton CJ
    Gene Ther; 2021 May; 28(5):242-255. PubMed ID: 32541928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors.
    Wang L; Calcedo R; Bell P; Lin J; Grant RL; Siegel DL; Wilson JM
    Hum Gene Ther; 2011 Nov; 22(11):1389-401. PubMed ID: 21476868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity.
    Pei X; Shao W; Xing A; Askew C; Chen X; Cui C; Abajas YL; Gerber DA; Merricks EP; Nichols TC; Li W; Samulski RJ; Li C
    Mol Ther Methods Clin Dev; 2020 Sep; 18():259-268. PubMed ID: 32637455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.
    Meliani A; Boisgerault F; Fitzpatrick Z; Marmier S; Leborgne C; Collaud F; Simon Sola M; Charles S; Ronzitti G; Vignaud A; van Wittenberghe L; Marolleau B; Jouen F; Tan S; Boyer O; Christophe O; Brisson AR; Maguire CA; Mingozzi F
    Blood Adv; 2017 Oct; 1(23):2019-2031. PubMed ID: 29296848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The deficient cleavage of M protein-bound IgG by IdeS: insight into the escape of Streptococcus pyogenes from antibody-mediated immunity.
    Su YF; Chuang WJ; Wang SM; Chen WY; Chiang-Ni C; Lin YS; Wu JJ; Liu CC
    Mol Immunol; 2011 Oct; 49(1-2):134-42. PubMed ID: 21925735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.
    Wang L; Calcedo R; Wang H; Bell P; Grant R; Vandenberghe LH; Sanmiguel J; Morizono H; Batshaw ML; Wilson JM
    Mol Ther; 2010 Jan; 18(1):126-34. PubMed ID: 19888196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Neutralizing Antibody Production on AAV-PHP.B-Mediated Transduction of the Mouse Central Nervous System.
    Shinohara Y; Konno A; Nitta K; Matsuzaki Y; Yasui H; Suwa J; Hiromura K; Hirai H
    Mol Neurobiol; 2019 Jun; 56(6):4203-4214. PubMed ID: 30291583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes.
    Yang R; Otten MA; Hellmark T; Collin M; Björck L; Zhao MH; Daha MR; Segelmark M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2479-86. PubMed ID: 20219834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.
    Jiang H; Couto LB; Patarroyo-White S; Liu T; Nagy D; Vargas JA; Zhou S; Scallan CD; Sommer J; Vijay S; Mingozzi F; High KA; Pierce GF
    Blood; 2006 Nov; 108(10):3321-8. PubMed ID: 16868252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of adeno-associated virus neutralizing antibody activity for clinical application.
    Wang M; Crosby A; Hastie E; Samulski JJ; McPhee S; Joshua G; Samulski RJ; Li C
    Gene Ther; 2015 Dec; 22(12):984-92. PubMed ID: 26125606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.